Neil Ettinger, MD
Pulmonary Disease · Chesterfield, MONPI 1619086451
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $52,405 of the $70,878 with a category attached, or 73.9%. Boehringer Ingelheim accounts for 81.5% of it on its own, with 50 other manufacturers making up the rest. Among pulmonary disease clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 866 payments — averaging $81.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$58K
- GSK$2K
- AstraZeneca$2K
- Insmed, Inc.$865
- Regeneron Healthcare Solutions, Inc.$755
- Sanofi$639
- plus $7K from 45 others
Across 876 payments — averaging $3887.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$816K
- Boehringer Ingelheim$522K
- United Therapeutics Corporation$457K
- Roche Products Limited$435K
- E.r. Squibb & Sons, L.L.C.$319K
- Genentech, Inc.$155K
- plus $702K from 14 others
What the payments were for
- Speaking & faculty fees$52,40574%
- Travel & lodging$1,8613%
- Food & beverage$16,54823%
- Education$640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$28,657
- ILLUMISITE$141
- Arikayce$114
How this compares
$70,878 in reported general payments places this provider in the 90th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 197 | $2,664,433 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 914 | $771,659 |
| OpsumitMacitentan | 46 | $589,268 |
| Pirfenidone | 100 | $230,517 |
| Breo ElliptaFluticasone/Vilanterol | 229 | $151,188 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 96 | $78,348 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 106 | $70,601 |
| XareltoRivaroxaban | 85 | $68,508 |
| AdcircaTadalafil | 14 | $66,745 |
| EliquisApixaban | 68 | $63,077 |
| Spiriva RespimatTiotropium Bromide | 64 | $54,544 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 44 | $32,952 |
| Incruse ElliptaUmeclidinium Bromide | 59 | $32,261 |
| SymbicortBudesonide/Formoterol Fumarate | 69 | $22,291 |
| NeuproRotigotine | 15 | $19,393 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat | $57,764 | $2,751,929305 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $2,195 | $1,033,5861,333 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $501 | $589,26846 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,851 | $104,673176 claims |
| Johnson & JohnsonXarelto | $551 | $68,50885 claims |
| United Therapeutics CorporationAdcirca | $499 | $66,74514 claims |
| PfizerEliquis, Abrysvo | $269 | $65,99979 claims |
| Covis Pharma GmbHAlvesco | $12 | $12,68622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 295 pulmonary disease providers in Missouri.
Other pulmonary disease in Chesterfield
- Bobby ShahChesterfield$241K
- Kristen FisherChesterfield$15K
- Humam FarahHannibal$840K
- Derek ByersSaint Louis$835K
- Alexander ChenSaint Louis$679K
- Joseph OjileSaint Louis$538K
- Munaf SiyamwalaIndependence$413K
- Edward CharbekSaint Louis$372K
- Adeel KhanWashington$316K
- Marin KollefSaint Louis$264K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.